PH — Parker-Hannifin Corporation

There is a real split as of 2026-09-13: the sell-side is emphatically bullish (consensus Buy, 26 Buys vs. 1 Sell, targets raised post-earnings to UBS $1,250, Susquehanna $1,250, Citigroup $1,232, Truist $1,358, consensus ~$1,154–$1,204), while the tape has cooled hard — PH is down 11.15% in one month and 1.28% in the last week, off a 52-week high of $1,099.94 and only 1.24% above its 200-day average. That divergence reads as a valuation de-rating of a richly priced industrial (32.9x trailing, 27x forward) rather than a reaction to bad fundamentals, since the August 6, 2026 print was a beat-and-raise with 8.0% organic growth and record backlog.

This is not a decelerating story — it is an inflection that has already happened. Quarterly YoY revenue growth went from +3.7% in Sep-25 ($5.084B vs $4.904B), to +9.1% in Dec-25, +10.6% in Mar-26, and +9.8% in Jun-26 ($5.755B), i.e. low-single-digit growth in FY25's first quarter accelerating to a stable ~10% run-rate. Operating margin followed: 20.3% (Sep-25), 21.1% (Dec-25), 20.7% (Mar-26), then a step-change 23.9% in Jun-26 ($1.373B on $5.755B), lifting FY26 operating margin to 21.6% ($4.634B / $21.499B) from 20.7% in FY25, with gross margin up to 37.7% from 36.9%. Reported diluted EPS compounded more slowly (FY26 sum $28.49 vs FY25 $27.11, ~+5%) only because of the ~$3.82/share gap between GAAP and management's adjusted $32.31 — that gap is largely acquired-intangible amortization, not operational deterioration. Free cash flow is the cleanest confirmation: FY26 quarterly FCF of $693M, $768M, $881M, $1.563B sums to $3.905B versus $3.341B in FY25 (+17%), and the accruals ratio of −2.09% confirms cash is running ahead of reported earnings. The boom-quarter margin in Jun-26 may be partly mix/timing, but the direction — broadening industrial recovery plus 13.4% organic aerospace growth and a $12.8B backlog — is structural, not a blip.

Expensive versus its own history, full versus peers, but not insanely so for the quality. As of 2026-09-13 the stock trades at 32.88x trailing EPS of $28.929 versus a 5-year average P/E of 25.99 (~26% premium), 5.57x sales versus a 5-year average of 3.62x (~54% premium), 7.78x book, and 22.3x EV/EBITDA. On forward numbers it looks less stretched: $950.23 against FY27 consensus EPS of $35.129 is 27.0x, and management's own guide midpoint of $34.75 gives 27.3x — but that is still a ~3.1x PEG against high-single-digit EPS growth, and the FMP PEG of 6.607 flags the same thing. The dividend yield of 0.78% offers essentially no valuation support. Verdict: the multiple already embeds the margin story (30% adjusted segment operating margin target by FY31) and the aerospace aftermarket mix; you are paying a premium price for a good business, not a bargain price for a mediocre one.

The market is paying for guidance delivery plus M&A accretion, not for a turnaround that hasn't shown up. FY26 adjusted EPS of $32.31 against an FY27 guide of $34.25–$35.25 is +6% to +9% growth, and at $950.23 that is ~27x forward — so in-line execution roughly justifies today's price and nothing more. The asymmetry is in the multiple: a slip to ~5% organic growth or a stumble integrating the $9.25B Filtration Group deal compresses the multiple toward the 26x historical average, which on unchanged FY27 EPS implies roughly $900 — multiple risk dominates earnings risk here. Conversely, any upward EPS revision toward the high-$30s (deal accretion plus buybacks) with the multiple holding near 29–30x puts the stock back over $1,100. Watch the Aug-21, 2026 10-K/10-Q catch-up: GAAP EPS of $28.49 versus adjusted $32.31 means screens that key off reported P/E will keep calling this ~33x while cash-flow-focused investors see a ~3.3% FCF yield.

Corrective pullback inside an intact uptrend, not yet an oversold buy signal. As of 2026-09-13, RSI(14) stood at 39.84 — weak momentum but shy of the ~30 oversold threshold — with price 4.26% below the 20-day average (≈$993), 3.97% below the 50-day (≈$990) and only 1.24% above the 200-day (≈$939), all within a 52-week range of $715.37–$1,099.94. Returns of −11.15% over one month and −1.28% over one week contrast with +5.17% over three months and +6.78% over six months, i.e. a sharp de-rating from an overbought peak rather than a breakdown. The timing implication: the 200-day near $939 is the line that matters — a hold there with RSI washing toward 30 is a reasonable accumulation zone, whereas a decisive break below it alongside a failure to reclaim the ~$990 50-day would signal the multiple compression has further to run.

• Higher-for-longer rates and industrial capex sensitivity: elevated borrowing costs have kept some cyclical capital spending sluggish, and a 27x forward multiple on a machinery company is duration-sensitive — any rate back-up pressures the multiple even if orders hold.
• Aerospace and defense upcycle: 13.4% organic segment growth in Q4 FY26 on commercial OEM build rates and high-margin aftermarket demand is the single biggest earnings tailwind, and it is tied to build-rate schedules and defense budgets Parker does not control.
• Broadening industrial recovery: management flagged early recovery signs in electronics and Asia-Pacific, which is what turns a ~10% organic print into a durable multi-year cycle rather than a one-quarter spike.
• Tariffs, trade policy and supply-chain regionalization: a global manufacturing footprint cuts both ways — localization and reshoring demand for motion-control content is a tailwind, while tariff cost pass-through and FX translation are live headwinds.
• Financing conditions for M&A: the $9.25B Filtration Group transaction and CIRCOR Aerospace are debt-funded, and even with net debt/EBITDA at 1.4x and S&P's positive outlook on the BBB+ rating, a higher-rate environment raises the cost of the acquisition-driven growth model.

• Q1 FY27 earnings on November 5, 2026 — the first hard test of whether the ~7% organic growth guide and the $12.8B backlog actually convert into orders and revenue, and the first clean look at post-acquisition financials.
• Closing, regulatory milestones and integration tracking on the $9.25B Filtration Group acquisition and CIRCOR Aerospace — these shift the revenue mix toward recurring consumable/aftermarket streams and are the main source of upside to the $34.25–$35.25 FY27 EPS guide.
• Delivery against the newly introduced FY31 target of a 30% adjusted segment operating margin (up from the prior 27%), plus continued capital deployment via buybacks and bolt-ons supported by 1.4x net leverage.
• Sell-side target revision momentum following the August beat (targets already at $1,232–$1,358) and potential sector rotation back into high-quality industrials if rate expectations ease.

• Multiple compression: at 32.9x trailing and ~27x forward versus a 25.99x five-year average, PH de-rates disproportionately fast if growth disappoints — a return to the historical average multiple on unchanged FY27 EPS implies roughly $900, below today's price.
• Industrial cycle stall: the high-single-digit organic growth assumption depends on a broadening recovery that has been called 'initial signs' only; if electronics/Asia-Pacific momentum fades, the revenue base reverts toward the +3.7% seen in Sep-25.
• M&A execution and leverage: the $9.25B Filtration Group transaction is large relative to recent deals and is debt-funded — integration missteps, delayed closings or a leverage step-up would hit both the earnings guide and the credit narrative.
• Aerospace concentration: the highest-margin growth is coming from commercial OEM build rates and aftermarket; any build-rate normalization or aftermarket destocking strikes exactly where margins expanded most (the 23.9% Q4 FY26 operating margin).
• Balance-sheet tightness at the margin: cash of $501M against $6.680B of long-term debt and a 1.262 current ratio (0.743 quick ratio) leaves little slack if the cycle turns while the acquisition closes.

Parker-Hannifin is a genuinely improved business — FY26 revenue $21.5B (+8.3%), operating margin up to 21.6% from 20.7%, $3.9B of free cash flow (+17%), record $12.8B backlog, 1.4x net leverage and a 14% ROIC — and the inflection from ~4% to ~10% organic growth is real, not a blip. The problem is price, not the company: as of 2026-09-13 the stock trades at roughly 27x FY27 consensus EPS for high-single-digit EPS growth, against a 26x five-year average and a 5.6x sales multiple versus a 3.6x historical norm, while the tape has turned (-11.15% in a month, RSI 39.84, price below both short moving averages). At ~$950 this is a quality-compounder hold or accumulate-on-weakness situation near the ~$939 200-day, not a fresh buy — my own fair-value work lands around $1,015, roughly 7% above spot, so the risk/reward is balanced rather than compelling.

Applied a 29x forward P/E to FY27 EPS of $35.00 (management's $34.25–$35.25 guide midpoint of $34.75, nudged up to the $35.13 consensus) — a justified multiple between the 25.99x five-year average trailing P/E and the current ~33x trailing / 27x forward level, warranted by the margin roadmap to 30% adjusted segment operating margin by FY31 and the aerospace aftermarket mix, but capped by high-single-digit EPS growth — yielding $1,015. Cross-checked with a required FCF yield: ~$4.2B of forward free cash flow (FY26's $3.905B grown ~8%) capitalized at 3.0–3.4% against ~$6.2B net debt and ~126.1M shares gives roughly $930–$1,060, centering near $990–$1,000, so the two methods bracket a fair value in the low $1,000s.